PGR and neoplasm: We have reported earlier that ER+/PgR-negative tumours are more likely to relapse on tamoxifen (Tovey et al, 2005), and a number of other laboratory studies report a reduction in PgR expression in ER+ cells that is consistent with acquired tamoxifen resistance (Scott et al, 2007).